Christensen J M, Limsakun T, Smith B B, Hollingshead N, Huber M
College of Pharmacy, Oregon State University, Corvallis, Oregon 97331-3507, USA.
J Vet Pharmacol Ther. 2001 Feb;24(1):23-33. doi: 10.1046/j.1365-2885.2001.00302.x.
Plasma concentration time curves following intravenous (i.v.) administration of 1.5 mg/kg of ranitidine, 0.2 mg/kg, 0.4 mg/kg and 0.8 mg/kg of omeprazole, respectively, were analysed in six llamas. Plasma profiles after i.v. administration of both drugs showed plasma concentrations declining in a biexponential manner with a rapid distribution phase. Pharmacokinetics parameters after ranitidine administration to six llamas showed a mean elimination half-life of 1.53 +/- 0.26 h. The mean volume of distribution (Vdss) in llamas was 1.77 +/- 0.31 L/kg, and mean body clearance in llamas was 0.778 +/- 0.109 L/kg/h. Ranitidine produced only a small transitory (<1 h) decline in acid production when administered i.v. at a dose of 1.5 mg/kg. Omeprazole showed dose-dependent nonlinear pharmacokinetics. The mean half-life of 0.2 mg/kg i.v. omeprazole was shorter than that of 0.4 and 0.8 mg/kg i.v. omeprazole, i.e. 0.61, 0.72 and 1.07 h, respectively. The area under the curve (AUC) and mean residence time (MRT) increased with increasing dose, while clearance decreased as dose increased. The decline in acid production following 0.2 mg/kg i.v. omeprazole was highly variable and did not produce a clinically useful suppression of third compartment acid production. In contrast, both 0.4 mg/kg and 0.8 mg/kg omeprazole i.v. administration significantly reduced third compartment acid production. The reduction in acid production following 0.8 mg/kg omeprazole was not significantly greater than the reduction observed following 0.4 mg/kg dosage. Misoprostol (10 microg/kg) was administered i.v. in an absolute alcohol solution. Two animals collapsed following drug administration. While the side-effects could have been produced by either misoprostol or the alcohol vehicle, the clinical changes were more consistent with an adverse drug reaction. Unfortunately, the limitation of UV detection did not provide the sensitivity needed to quantify the amount of misoprostol in llama plasma, and the pharmacokinetics could not be evaluated.
分别给6只美洲驼静脉注射1.5毫克/千克雷尼替丁、0.2毫克/千克、0.4毫克/千克和0.8毫克/千克奥美拉唑后,分析其血浆浓度-时间曲线。静脉注射这两种药物后的血浆浓度曲线显示,血浆浓度呈双指数下降,分布相迅速。给6只美洲驼注射雷尼替丁后的药代动力学参数显示,平均消除半衰期为1.53±0.26小时。美洲驼的平均分布容积(Vdss)为1.77±0.31升/千克,平均机体清除率为0.778±0.109升/千克/小时。静脉注射1.5毫克/千克剂量的雷尼替丁时,仅使胃酸分泌产生短暂(<1小时)的小幅下降。奥美拉唑显示出剂量依赖性非线性药代动力学。静脉注射0.2毫克/千克奥美拉唑的平均半衰期短于静脉注射0.4毫克/千克和0.8毫克/千克奥美拉唑的平均半衰期,分别为0.61、0.72和1.07小时。曲线下面积(AUC)和平均驻留时间(MRT)随剂量增加而增加,而清除率随剂量增加而降低。静脉注射0.2毫克/千克奥美拉唑后胃酸分泌的下降差异很大,并未对第三腔室胃酸分泌产生临床上有用的抑制作用。相比之下,静脉注射0.4毫克/千克和0.8毫克/千克奥美拉唑均显著降低了第三腔室胃酸分泌。静脉注射0.8毫克/千克奥美拉唑后胃酸分泌的降低幅度并不显著大于静脉注射0.4毫克/千克剂量后的降低幅度。米索前列醇(10微克/千克)以无水乙醇溶液静脉注射。给药后有两只动物虚脱。虽然副作用可能是由米索前列醇或乙醇溶媒引起的,但临床变化更符合药物不良反应。不幸的是,紫外检测的局限性无法提供定量美洲驼血浆中米索前列醇含量所需的灵敏度,因此无法评估其药代动力学。